XML 162 R146.htm IDEA: XBRL DOCUMENT
v3.20.4

Commitments and Contingencies (Details Narrative) (Brooklyn ImmunoTherapeutics, LLC) - USD ($) |  |  |  |  | 3 Months Ended | 6 Months Ended | 9 Months Ended | 12 Months Ended |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Jul. 06, 2020 | Dec. 13, 2019 | Nov. 07, 2018 | Jul. 31, 2018 | Sep. 30, 2020 | Sep. 30, 2019 | Jun. 30, 2020 | Sep. 30, 2020 | Sep. 30, 2019 | Dec. 31, 2019 | Dec. 31, 2018 | Aug. 13, 2020 | Jan. 02, 2019
Concentration risk percentage |  |  |  |  | 100.00% | 100.00% |  | 100.00% | 100.00% | 100.00% | 100.00% |  |
Operating lease liabilities |  |  |  |  | $ 5,000 |  |  | $ 5,000 |  | $ 3,300,000 | $ 3,458,000 |  | $ 3,458,000
Brooklyn Immunotherapeutics, LLC [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Sublease payments |  |  |  |  |  |  |  | 58,957 | $ 6,535 |  |  |  |
Operating lease liabilities |  |  |  |  | $ 100,700 |  |  | $ 100,700 |  | $ 103,056 |  |  |
Brooklyn Immunotherapeutics, LLC [Member] | USF License Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty payable percentage |  |  |  |  |  |  |  |  |  | 7.00% |  |  |
Brooklyn Immunotherapeutics, LLC [Member] | IRX Royalty Agreements [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Concentration risk percentage |  |  |  |  |  |  |  |  |  | 1.00% |  |  |
Brooklyn Immunotherapeutics, LLC [Member] | Termination Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Concentration risk percentage |  |  |  |  |  |  | 6.00% |  |  |  |  |  |
Brooklyn Immunotherapeutics, LLC [Member] | Investor Royalty Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Concentration risk percentage |  |  | 4.00% |  |  |  |  |  |  |  |  |  |
Brooklyn Immunotherapeutics, LLC [Member] | CEO Separation Agreement [Member] | Chief Executive Officer [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Severance pay |  | $ 225,000 |  | $ 275,000 |  |  |  |  |  |  |  |  |
Unused vacation time |  | 37,518 |  |  |  |  |  |  |  |  |  |  |
Health and dental insurance plan |  | $ 14,032 |  |  |  |  |  |  |  |  |  |  |
Brooklyn Immunotherapeutics, LLC [Member] | IRX Therapeutics, Inc [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Business combination percentage |  |  |  |  |  |  |  |  |  | 25.00% |  |  |
Legal settlements |  |  |  |  |  |  |  |  |  |  |  | $ 150,000 |
Brooklyn Immunotherapeutics, LLC [Member] | BIT Merger Sub, Inc [Member] | Employee Agreements [Member] | Chief Executive Officer [Member] | January 8, 2021 [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Employee, retention payment | $ 200,000 |  |  |  |  |  |  |  |  |  |  |  |
Brooklyn Immunotherapeutics, LLC [Member] | BIT Merger Sub, Inc [Member] | Employee Agreements [Member] | Chief Executive Officer [Member] | July 8, 2021 [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Employee, retention payment | $ 200,000 |  |  |  |  |  |  |  |  |  |  |  |

X
- Definition Employee, retention payment. + References No definition available. + Details
Name: | NTN_EmployeeRetentionPayment
Namespace Prefix: | NTN_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Health and dental insurance plan. + References No definition available. + Details
Name: | NTN_HealthAndDentalInsurancePlan
Namespace Prefix: | NTN_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Royalty payable percentage. + References No definition available. + Details
Name: | NTN_RoyaltyPayablePercentage
Namespace Prefix: | NTN_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Severance pay. + References No definition available. + Details
Name: | NTN_SeverancePay
Namespace Prefix: | NTN_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Unused vacation time. + References No definition available. + Details
Name: | NTN_UnusedVacationTime
Namespace Prefix: | NTN_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Percentage of voting equity interests acquired at the acquisition date in the business combination. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463 + Details
Name: | us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592 + Details
Name: | us-gaap_ConcentrationRiskPercentage1
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of loss contingency liability. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349 + Details
Name: | us-gaap_LossContingencyAccrualAtCarryingValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Present value of lessee's discounted obligation for lease payments from operating lease. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 45 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977 + Details
Name: | us-gaap_OperatingLeaseLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of sublease income excluding finance and operating lease expense. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 50 -Paragraph 4 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 55 -Paragraph 53 -URI http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971 + Details
Name: | us-gaap_SubleaseIncome
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_ConsolidatedEntitiesAxis=NTN_BrooklynImmunotherpeuticsLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=NTN_USFLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=NTN_IRXRoyaltyAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=NTN_TerminationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=NTN_InvestorRoyaltyAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=NTN_CeoSeparationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=NTN_IRXTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=NTN_BITMergerSubIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=NTN_EmployeeAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AwardDateAxis=NTN_JanuaryEightTwoThousandTwentyOneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AwardDateAxis=NTN_JulyEightTwoThousandTwentyOneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |